FDA Inspection 1220409 — Amgen, Inc.

Amgen, Inc. — FEI 2026154

The FDA completed an inspection of Amgen, Inc. on September 14, 2023 in Thousand Oaks, CA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
September 14, 2023
Fiscal Year
2023
Product Type
Drugs
Project Area
Bioresearch Monitoring
Location
Thousand Oaks, CA (United States)

Additional Details

Sponsor, Contract Research Organization